Jian Q. (Michael) Yu, MD, FACNM, FRCPC

This physician is not currently rated. Why?

Request an Appointment

Call 888-369-2427

Request Online

Clinical Locations

Primary Location
Fox Chase Cancer Center

Chief, Nuclear Medicine and PET

Professor, Department of Diagnostic Imaging

Specialties

Head & Neck Cancer ;
Liver, Gall Bladder & Bile Duct Cancer ;
Myeloma ;
Neuroendocrine Tumors ;
Pancreatic Cancer ;
Prostate Cancer ;
Thyroid Cancer

Treatment Focus

My main work is in diagnostic imaging using radiotracers for staging, follow-up, and monitoring of various tumors. I also treat patients with unsealed source radiotracer for thyroid cancer, NHL, pancreatic cancer, and bone pain palliation. I’m authorized user for SIR-sphere and Therasphere as well.

Research Program

Cancer Signaling and Microenvironment

Key Awards

Nuclear Medicine

Treatment Philosophy

Patient first.

Educational Background

Fellow, American College of Nuclear Medicine, 2009
Fellow, American College of Nuclear Physicians, 2009
Fellow, Royal College of Physicians, Canada, 2008
MD, Beijing Medical University, Beijing, China, 1987

Certifications

Diplomate, American Board of Nuclear Medicine, certified 2003, recertified 2013
Nuclear Medicine Specialist, Royal College of Physicians and Surgeons of Canada, 2008

Memberships

American College of Nuclear Medicine
American College of Radiology
Society of Nuclear Medicine and Molecular Imaging
Radiologic Society of North American

Honors & Awards

Philadelphia Magazine Top Docs, 2016, 2018-20
Outstanding Contribution Award, American College of Radiology Imaging Network, 2010
America's Top Doctors^®, 2017

Research Interests

Novel tracer
Early phase clinical trials

Selected Publications

Skripova V., Vlasenkova R., Zhou Y., Astsaturov I.,Kiyamova R., Identification of new regulators of pancreatic cancer cell sensitivity to oxaliplatin and cisplatin. Molecules. 27(4)2022. PMC8875979. https://www.ncbi.nlm.nih.gov/pubmed/35209078.

Doss M., Nakhoda S.K., Li Y., Yu J.Q., Covid-19 vaccine-related local fdg uptake. Clin Nucl Med. 46(5): 439-441, 2021. https://www.ncbi.nlm.nih.gov/pubmed/33661194.

Yu JQ, Zhuang HM, Xiu Y, Talati E, Alavi A. Demonstration of Increased FDG Activity in Rosai-Dorfman Disease on Positron Emission Tomography. Clinical Nuclear Medicine 29 (3): 209-210 MAR 2004 (PMID: 15162996) PubMed

Yu JQ, Kumar R, Xiu Y, Alavi A, and Zhuang HM. Diffuse FDG uptake in the lungs in patient with aspiration pneumonia on Positron Emission Tomographic imaging. Clinical Nuclear Medicine 29 (9): 567-568 SEPT 2004 (PMID: 15311127) PubMed

Yu JQ, Milestone BD, Parsons R, Doss M, Haas N: Findings of Intra-Mediastinal Gossypiboma with F-18 FDG PET in a Melanoma Patient. Clinical Nuclear Medicine 33(5):344-345, May 2008 (PMID: 18431152) PubMed

Doss M, Zhang JJ, Bélanger MJ, Stubbs JB, Hostetler EB, Alpaugh RK, Kolb H, Yu JQ: Biodistribution and Radiation Dosimetry of the Hypoxia Marker 18F–HX4 in monkeys and humans determined from whole-body PET/CT, Nuclear Medicine Communications 31(12): 1016-24; [Epub 2010 Oct 13] (PMID: 20948452/NIHMSID#: 259162/PMCID: PMC3016990) PubMed

Reddy S, Shaller CC, Doss M, Shchaveleva I, Yu JQ, Robinson MK: Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clinical Cancer Research, 2011 Mar.15; 17(6):1509-1520; [Epub 2010 Dec.21] (PMID: 21177408/PMCID: PMC3060271) PubMed

Miller J, Doss M, McQuillen R, Shaller CC, Tolner B, Yu JQ, Chester K, Adams GP, Robinson MK: Impact of Expression System on the Function of the C6.5db PET Radiotracer, Tumor Biology, 2012; 33(3):617-27 [Epub 2012 March 1], PMID:22383295 PubMed

Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig CJ, Yu JQ, Vallabhajosula S, Larson SM, Schoder H, English P, Neuberg DS, Martin P, Ely SA, Courtney R, Shaik N, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT and Shapiro GI: Selective CDK4/6 Inhibition with Tumor Responses by PD0332991 in Patients with Mantle Cell Lymphoma, Blood, 2012 119: 4597-4607 with editorial, [Epub 2012 March 1], PMID: 22383795 PubMed

Doss M, Kolb HC, Zhang JJ, Bélanger M, Stubbs JB, Stabin MG, Hostetler ED, Alpaugh RK, von Mehren M, Walsh JC, Haka M, Mocharla VP, Yu JQ*: Biodistribution and Radiation Dosimetry of the Integrin Marker 18F-RGD-K5 in monkeys and humans determined from whole-body PET/CT, Journal of Nuclear Medicine 2012; 53:787-795 [Epub 2012 Apr 12], PMID: 22499613 PubMed... Expand

Divgi C, Uzzo R, Gatsonis C, Bartz R, Treutner S, Yu JQ, Chen D, Carrasquillo J, Larson S, Bevan P, Russo P: PET/CT Identification of Clear Cell Renal Cell Carcinoma: Results of the REDECT Trial. Journal of Clinical Oncology, January 10, 2013: vol. 31, no. 2, 187-194. [Epub Dec. 3, 2012], PMID: 23213092 PubMed

Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, Burtness B, Mehra R, Galloway T, Ridge J: Extranodal extension of Metastatic Papillary Thyroid Carcinoma: Correlation with biochemical endpoints, nodal persistence and systemic disease progression. Thyroid, 23(9), 1099-1105 [Epub Feb. 19, 2013], PMID: 23421588 PubMed

Savir-Baruch B, Banks KP, McConathy JE, Molchanova-Cook OP, Parent EE, Takalkar A, Tulchinsky M, Yu JQ, Subramaniam RM, Schuster DM: ACR- ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine- PET/CT for Recurrent Prostate Cancer. Clin Nucl Med. 01 Dec 2018, 43 (12): 909-917, PMID: 30325827

GL Andriole, L Kostakoglu, A Chau, F Duan, U Mahmood, DA Mankoff, DM Schuster, BA Siegel, LOCATE Study Group: The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Management of Patients with Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. J Urol. 2019 Feb;201(2):322-331, PMID: 30179618

VJ Lowe, F Duan, RM Subramaniam, JD Sicks, J Romanoff, T Bartel, JQM Yu, B Nussenbaum, J Richmon, CD Arnold, D Cognetti, BC Stack Jr: A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results from ACRIN 6685. Journal of Clinical Oncology Jul 10;37 (20):1704-1712. PMID: 30768363; PMCID: PMC6638599

E Sorenson, F Lambreton, JQ Yu, T Li, CS Denlinger, JE Meyer, ER Sigurdson, JM Farma: Impact of PET/CT for Restaging Patients with Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation, Journal of Surgical Research 243, 242-248, PMID: 31229791

M von Mehren, S George, M Heinrich, S Schuetze, J Yap, JQ Yu, A Abbott, S Litwin, J Crowley, M Belinsky, K Janeway, J Hornick, D Flieder, R Chugh, L Rink, and A Van den Abbeele: Linsitinib (OSI-906) for the treatment of Adult and Pediatric Wild Type Gastrointestinal Stromal Tumors, a SARC Phase II study. Clinical Cancer Research, 2020;26:1837–45. PMID: 31792037

AA Solanki, B Savir-Baruch, SL Liauw, J Michalski, JD Tward, N Vapiwala, EJ Teoh on behalf of the LOCATE study group: LP Adler, GL Andriole, LH Belkoff, D Burzon, A Chau, P Dato, F Duan, M Farwell, S Fogelson, P Gardiner, L Hanna, JM Hoffman, C Intenzo, D Josephson, J Kaminetsky, M Kipper, L Kostakoglu, B Krynyckyi, KE Linder, U Mahmood, H Marques, D Mankoff, J McConathy, J Melnick, MP Miller, W Oh, S Philips, J Rose, B Savir-Baruch, DM Schuster, BA Siegel, DJ Stevens, A Tewari, P Twardowski, P Ward, M Wasserman, S Weick, JQ.(Michael) Yu: 18F-Fluciclovine positron emission tomography in men with biochemical recurrence of prostate cancer after radical prostatectomy and planning to undergo salvage radiotherapy: Results from LOCATE, Practical Radiation Oncology, Vol 10, Issue 5, September–October 2020, Pages 354-362 Collapse

Additional Publications

My NCBI

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.